• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cloning short DNA into plasmids by one ‐step PCR
ConclusionsFree from the limitations of restriction enzyme sites and omitting the ligation process, our method offers a flexible and economical option of plasmid construction.Key pointsSignificant findings of the studyA method to clone short DNA into plasmids was found.What this study addsOur study provides a flexible and economical option to clone short DNA into plasmids.
Source: Thoracic Cancer - October 4, 2020 Category: Cancer & Oncology Authors: Cheng ‐Cheng Tao, Ying Yang, Fang Li, Ling Qiao, Yue Wu, Xiao‐Dong Sun, Yuan‐Yuan Zhang, Chang‐Long Li Tags: TECHNOLOGICAL NOTE Source Type: research

Endothelial Cell-Derived TGF- β Promotes Epithelial-Mesenchymal Transition via CD133 in HBx-Infected Hepatoma Cells
Conclusion: The study indicates that secretory factors like TGF-β from neighboring endothelial cells may enhance expression of CD133 and impart an aggressive EMT phenotype to HBx-infected hepatoma cells in HBV induced HCC. Introduction Hepatocellular Carcinoma (HCC) is one of the most common cancer worldwide, representing approximately 4% of all malignancies (1). It has been estimated that more than 50% of HCC cases in the world are associated with hepatitis B virus (HBV) (2). HBV is a partially double stranded DNA virus belonging to the Hepadnavirus family. The HBV genome is 3.2 kb in size and contains fou...
Source: Frontiers in Oncology - April 23, 2019 Category: Cancer & Oncology Source Type: research

Abstract A31: Targeting APC loss using synthetic lethality in Colorectal Cancer
Conclusions: We have identified seven genes as potential therapeutic targets and a number of FDA-approved compounds, which could potentially be new selective therapies for 80% of CRC patients. Currently we are validating these findings and investigating the mechanism of synthetic lethality with APC mutation. To further validate our findings we are also exploring whether these results extend to other CRC cell lines with different mutational backgrounds, this will help us access how many patients may benefit from our novel therapeutic targets.Acknowledgments: We would like to thank Bowel and Cancer Research and The Rosetree ...
Source: Molecular Cancer Therapeutics - October 2, 2017 Category: Cancer & Oncology Authors: Shailes, H., Bridge, G., Foxler, D., Sharp, T. V., Silver, A., Martin, S. A. Tags: Finding Synthetic Lethal Interactions through Functional Genomics: Poster Presentations - Proffered Abstracts Source Type: research

Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer.
CONCLUSIONS: The results suggest that BST-2 is involved in tumor progression and serves as an independent prognostic classifier for patients with GC. Because BST-2 is expressed on the cell membrane, BST-2 could be a therapeutic target for GC, CRC, and ESCC. PMID: 26832883 [PubMed - as supplied by publisher]
Source: Ann Oncol - February 1, 2016 Category: Cancer & Oncology Authors: Mukai S, Oue N, Oshima T, Mukai R, Tatsumoto Y, Sakamoto N, Sentani K, Tanabe K, Egi H, Hinoi T, Ohdan H, Yasui W Tags: Ann Surg Oncol Source Type: research

Overexpression of Transmembrane Protein BST2 is Associated with Poor Survival of Patients with Esophageal, Gastric, or Colorectal Cancer
Conclusions The results suggest that BST-2 is involved in tumor progression and serves as an independent prognostic classifier for patients with GC. Because BST-2 is expressed on the cell membrane, BST-2 could be a therapeutic target for GC, CRC, and ESCC.
Source: Annals of Surgical Oncology - February 1, 2016 Category: Cancer & Oncology Source Type: research

Abstract C171: Human anti-Nucleolin recombinant immunoagents as new potential tools for melanoma treatment
Immunotherapy and immune-based anti-cancer molecules represent a valid strategy to fight cancer. However, the choice of tumor-specific surface molecules for the selective targeting of cancer cells still represents a critical step in the study design for the development of new therapeutic approaches. Notably, the development of phage-display technology for the selection of fully human single chain antibody fragments (scFvs) and complete antibodies directed toward tumor-associated antigens has represented a significant advancement for immunotherapy.Nucleolin (NCL) is one of the most abundant non-ribosomal proteins in the nuc...
Source: Molecular Cancer Therapeutics - January 7, 2016 Category: Cancer & Oncology Authors: Braddom, A., Richmond, T., Sheetz, T., Reese, E., Tessari, A., Tober, K., Burd, C. E., De Lorenzo, C., Martin, E. W., Coppola, V., Tweedle, M. F., Oberyszyn, T., Croce, C. M., Palmieri, D. Tags: Therapeutic Agents: Biological: Poster Presentations - Proffered Abstracts Source Type: research

Abstract 905: Influence of high fat diet and APC status on epigenetic regulation of FXR in colon cells
We examined the effects on CpG pmethylation of Fxr, and expression of FXR, peroxisome-proliferator activated receptor-gamma (PPARγ), and cyclooxygenase-2 (COX-2) mRNA. Also, we studied the influence of APC status on CpG methylation of the Fxr gene, and expression of FXR, ileal bile acid-binding protein (IBABP), small heterodimer partner (SHP), and COX-2 mRNA in normal colonic mucosa and colon tumors from APCMin/+ mice. Mice fed the HFD had reduced (60%) Fxr promoter methylation and increased (2∼3-fold) FXR, COX-2, and PPARγ mRNA levels. Conversely, APC-deficiency was associated with constitutive hypermethylation of the...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Selmin, O. I., Lyon, A. M., Fang, C., Doetschman, T. C., Thompson, P. A., Martinez, J. D., Smith, J., Lance, P. M., Romagnolo, D. F. Tags: Prevention Research Source Type: research

Abstract 694: Structure-function analysis of RPL18A, a putative binding target of rigosertib
Rigosertib (ON 01910.Na; RGS) is a clinical stage anticancer agent that causes spindle abnormalities and mitotic arrest in neoplastic cells. The drug inhibits PI3K and PLK1 signaling pathways, down regulates cyclin D1 expression and induces apoptosis. Previously, we reported identification of RPL18A (L18A), a protein from the large ribosomal subunit, as a putative binding target of RGS [Proc. AACR 2014, #4595]. Knock-down of L18A with siRNA caused apoptosis in cancer cell lines. Role of L18A in the function of the ribosome is not known. Goal of this study was to conduct structure-function analysis of L18A and create defici...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Oussenko, I. A., Gupta, Y. K., Vasquez-Del Carpio, R., Ramana-Reddy, M. V., Aggarwal, A. K., Reddy, E. P., Holland, J. F., Ohnuma, T. Tags: Experimental and Molecular Therapeutics Source Type: research